TriangleNCT03735121 · OUTCOME
Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of HCPs
- Interval / dispersion
- Not reported
- Time frame
- After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)
What was measured
The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: Overall, how easy did you find atezolizumab SC administration? The responses to this question could be: Very easy; Fairly easy; Not at all easy. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.
Analysis population: Overall number analyzed included HCPs who completed Question 3 of the questionnaire.
Groups in this outcome
Part 2: Atezolizumab SC 1875 mg
Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire.
| Group | Source count |
|---|---|
| Part 2: Atezolizumab SC 1875 mg | 84 |
Reported measurements
Very easy
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Atezolizumab SC 1875 mg | 54.8 | Not reported | Not reported | Not reported | Not reported |
Fairly easy
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Atezolizumab SC 1875 mg | 34.5 | Not reported | Not reported | Not reported | Not reported |
Not at all easy
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 2: Atezolizumab SC 1875 mg | 10.7 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 54.8
- title
- Very easy
- categories
- measurements
- group Id
- OG000
- value
- 34.5
- title
- Fairly easy
- categories
- measurements
- group Id
- OG000
- value
- 10.7
- title
- Not at all easy
- denoms
- counts
- group Id
- OG000
- value
- 84
- units
- Participants
- description
- The HCP SC Perspective Questionnaire consisted of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction. HCPs who administered at least three doses of atezolizumab as a SC injection across all participants in Part 2 of this study responded to this questionnaire, of which question 3 is being reported here: Question 3: Overall, how easy did you find atezolizumab SC administration? The responses to this question could be: Very easy; Fairly easy; Not at all easy. HCPs were allowed to complete the questionnaire until the last participant completed their assessments (duration between the 'FPI in' date to 'LPLV' for Part 2). Percentages have been rounded to one decimal place.
- groups
- description
- Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity. HCPs who administered the SC formulation completed the HCP SC Perspective Questionnaire.
- id
- OG000
- title
- Part 2: Atezolizumab SC 1875 mg
- param Type
- NUMBER
- population Description
- Overall number analyzed included HCPs who completed Question 3 of the questionnaire.
- reporting Status
- POSTED
- time Frame
- After HCP has completed administering at least 3 doses of atezolizumab SC across all participants in Part 2 (Up to approximately 48 months)
- title
- Part 2: Percentage of HCPs by Their Response to Question 3 of the HCP SC Perspective Questionnaire
- type
- SECONDARY
- unit Of Measure
- percentage of HCPs
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice